Castle Biosciences, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
14843C105
SEDOL
BKLCWZ3
CIK
0001447362
castlebiosciences.com
LEI:
©
FIGI: BBG006YWVSR3
CSTL
Castle Biosciences, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Diagnostics & Research
AI
PROFILER
NAME
Castle Biosciences, Inc.
ISIN
US14843C1053
TICKER
CSTL
MIC
XNAS
REUTERS
CSTL.OQ
BLOOMBERG
CSTL US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 19.12.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 12.12.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new independent meta-analysis in Cancers assessing the efficacy of its DecisionDx-Melanoma test in predicting melanoma patient outcomes. The article, titled “The Prognostic Value of the 31-Gene ...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time. A live audio webcast of the C...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area’s top workplaces. Castle also earned thr...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Fri, 08.11.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting, being held Nov. 7-10, in Chicago. “At Castle, w...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.11.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s Esophagus test, which surpassed 25,000 test reports delivered since the Company acquired the test at the end of 2021. “At Castle, improving patient c...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Wed, 06.11.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the latest data from its prospective, multicenter DECIDE study exploring the impact of integrating DecisionDx-Melanoma test results into SLNB decision-making for patients recently diagnosed with melanoma. The update...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. “We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedi...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.10.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating a significant reduction in healthcare management costs and an improvement in the quality of life for patients with Barrett’s esophagus (BE) whose management is guided by its TissueCypher test....
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       Castle Biosciences
US14843C1053

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month: Guggenheim Securities Healthcare Innovation Conference on Nov. 11, 2024, at 2:30 p.m. East...
Read More
Castle Biosciences
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S